Transcriptional Repressor BCL11A in Erythroid Cells

Area of Science:

• Molecular Biology
• Genetics
• Hematology

Background:

• BCL11A is a transcription factor regulating the switch from fetal hemoglobin (HbF) to adult hemoglobin (HbA).
• Genome-wide association studies linked BCL11A to HbF regulation in erythroid cells, despite its known role in lymphoid development.
• BCL11A acts as a silencer of gamma-globin gene expression, crucial for HbF production.

Purpose of the Study:

• To investigate the role of BCL11A in erythroid cells and its potential as a therapeutic target for hemoglobinopathies.
• To identify and characterize regulatory elements controlling BCL11A expression in erythroid cells.
• To explore gene editing strategies for modulating BCL11A activity in the context of sickle cell disease (SCD) and beta-thalassemia.

Main Methods:

• Utilized CRISPR/Cas9 gene editing to target an erythroid-specific enhancer within the BCL11A gene.
• Investigated the function of a GATA-binding site within the enhancer, crucial for BCL11A expression.
• Advanced guide RNA targeting for clinical trials involving ex vivo editing of hematopoietic stem/progenitor cells (HSPCs).

Main Results:

• Disruption of the GATA-binding site in the BCL11A enhancer led to robust reactivation of HbF.
• Erythroid-specific BCL11A loss rescued phenotypes in engineered sickle cell disease mouse models.
• Clinical trials demonstrated the feasibility of ex vivo CRISPR editing of HSPCs for SCD and beta-thalassemia therapy.

Conclusions:

• Downregulation of BCL11A is a viable therapeutic strategy for SCD and beta-thalassemia.
• Targeting the BCL11A enhancer, particularly the GATA-binding site, effectively reactivates HbF.
• Ex vivo CRISPR gene editing of HSPCs shows promise for treating hemoglobinopathies, with ongoing efforts to improve access, reduce costs, and explore in vivo approaches.